[ad_1] NANJING, China, 11 de noviembre de 2025/PRNewswire/ — Simcere Pharmaceutical Group (2096.HK) anunció que la proteína de fusión IL-2 mu-Fc (IL-2 mu-Fc), SIM0278, dirigida a células T reguladoras (Treg), ha entrado oficialmente en un […]
Tag: Simcere Pharmaceutical Group Limited
Das IL-2-Mutanten-Fusionsprotein SIM0278 von Simcere ist in die Phase II der klinischen Studien eingetreten
[ad_1] NANJING, China, 11. November 2025 /PRNewswire/ — Die Simcere Pharmaceutical Group (2096.HK) gab bekannt, dass ihr regulatorisches T-Zellen (Treg)-präferentielles IL-2-Mutanten-Fc-Fusionsprotein (IL-2 mu-Fc), SIM0278, offiziell in eine klinische Phase-II-Studie in China zur Behandlung von mittelschwerer bis […]
Lancement d’essais cliniques de phase II pour la protéine de fusion mutante de l’IL-2 de Simcere, la SIM0278
[ad_1] NANKIN, Chine, 11 novembre 2025 /PRNewswire/ — Simcere Pharmaceutical Group (2096.HK) a annoncé que la SIM0278, sa protéine de fusion Fc mutante de l’IL-2 (IL-2 mu-Fc) privilégiée pour les cellules T régulatrices (Treg), était officiellement entrée […]
Simcere’s IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
[ad_1] NANJING, China, Nov. 10, 2025 /PRNewswire/ — Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells (Treg) -preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study in […]
World Stroke Congress | TASTE-2 significantly reduces stroke disability
[ad_1] NANJING, China, Oct. 30, 2024 /PRNewswire/ — Oct 24th 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that a new clinical study with major clinical findings regarding Sanbexin (edaravone and dexborneol concentrated solution for injection) […]
